N.Y. Public Health Law § 2500-a: Test for phenylketonuria and other diseases and conditions

§ 2500-a. Test for phenylketonuria and other diseases and conditions.

1. It shall be the duty of the administrative officer or other person in

charge of each institution caring for infants twenty-eight days or less

of age and the person required in pursuance of the provisions of section

forty-one hundred thirty of this chapter to register the birth of a

child, to cause to have administered to every such infant or child in

its or his care a test for diseases and conditions designated by the

commissioner under regulations of the commissioner, and for:

(a) Phenylketonuria.

(b) Homozygous sickle cell disease.

(c) Hypothyroidism.

(d) Branched-chain ketonuria.

(e) Galactosemia.

(f) Homocystinuria.

(g) Critical congenital heart defects through pulse oximetry

screening.

(h) With regard to any newborn infant who is identified as, or

suspected of, having a hearing impairment as a result of a screening

conducted pursuant to section twenty-five hundred-g of this title, a

urine polymerase chain reaction (PCR) test for cytomegalovirus, unless

the parent of the infant objects thereto; provided that if the

commissioner determines that another test for cytomegalovirus is

diagnostically equivalent to or better than the urine polymerase chain

reaction test, the commissioner may, by regulation under this section,

allow or require the use of that other test.

(i) Adrenoleukodystrophy.

(j) Glucose-6-phosphate dehydrogenase deficiency using a quantitative

enzymatic test or other diagnostic test in cases where: the newborn

infant presents with hemolytic anemia, hemolytic jaundice, or

early-onset increasing neonatal jaundice, that is, jaundice (bilirubin

level greater than fortieth percentile for age in hours) persisting

beyond the day of birth through the week after birth; the newborn infant

has been admitted to the hospital for jaundice following birth; or the

biological parent of the newborn infant indicates a family, racial, or

ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including

having significant African, Asian, Mediterranean, or Middle Eastern

ancestry.

(k) Duchenne muscular dystrophy using a test validated by the

Wadsworth center for laboratories and research.

2. Testing, the recording of the results of such tests, tracking,

follow-up reviews and educational activities shall be performed at such

times and in such manner as may be prescribed by the commissioner. The

commissioner shall promulgate regulations setting forth the manner in

which information describing the purposes of the requirements of this

section shall be disseminated to parents or a guardian of the infant

tested.

3. The provisions of this section shall not apply in the case of any

infant or child whose parent or guardian is a member of a recognized

religious organization whose teachings and tenets are contrary to the

testing herein required and who notifies the person charged with having

such test administered of his objection thereto.